CAM
BPMC

Cormorant Asset Management’s Blueprint Medicines BPMC Stock Holding History

Cormorant Asset Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-150,000
Closed -$15.4M – 80
2021
Q3 		$15.4M Sell
150,000
-87,546
-37% -$8.15M 0.63% 41
2021
Q2 		$20.9M Sell
237,546
-9,654
-4% -$885K 0.71% 38
2021
Q1 		$24M Buy
247,200
+22,200
+10% +$2.22M 0.54% 40
2020
Q4 		$25.2M Sell
225,000
-50,000
-18% -$5.27M 0.6% 41
2020
Q3 		$25.5M Sell
275,000
-75,000
-21% -$5.78M 0.98% 33
2020
Q2 		$27.3M Sell
350,000
-100,000
-22% -$6.76M 1.04% 30
2020
Q1 		$26.3M Buy
450,000
+105,000
+30% +$6.76M 1.22% 27
2019
Q4 		$27.6M Sell
345,000
-148,000
-30% -$11.1M 1.1% 35
2019
Q3 		$36.2M Buy
493,000
+143,000
+41% +$12.4M 2.2% 13
2019
Q2 		$33M Sell
350,000
-100,000
-22% -$8.25M 1.9% 17
2019
Q1 		$36M Buy
450,000
+88,649
+25% +$6.55M 2.43% 12
2018
Q4 		$19.5M Sell
361,351
-18,649
-5% -$1.13M 1.58% 20
2018
Q3 		$29.7M Sell
380,000
-170,000
-31% -$11.8M 1.93% 20
2018
Q2 		$34.9M Buy
550,000
+117,937
+27% +$9.39M 2.58% 12
2018
Q1 		$39.6M Sell
432,063
-17,937
-4% -$1.55M 2.95% 7
2017
Q4 		$33.9M Buy
450,000
+375,000
+500% +$26.4M 3.55% 6
2017
Q3 		$5.22M Sell
75,000
-292,900
-80% -$15.7M 0.92% 32
2017
Q2 		$18.6M Sell
367,900
-232,100
-39% -$9.86M 3.09% 11
2017
Q1 		$24M Sell
600,000
-241,752
-29% -$8.66M 3.48% 7
2016
Q4 		$23.6M Buy
841,752
+542,882
+182% +$16.4M 3.18% 10
2016
Q3 		$8.88M Buy
298,870
+197,644
+195% +$4.91M 0.98% 32
2016
Q2 		$2.05M Buy
+101,226
New +$1.84M 0.29% 61
2016
Q1 		– Sell
-100,000
Closed -$2.63M – 85
2015
Q4 		$2.63M Hold
100,000
– – 0.32% 57
2015
Q3 		$2.13M Hold
100,000
– – 0.34% 57
2015
Q2 		$2.65M Buy
+100,000
New +$2.86M 0.35% 55

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cormorant Asset Management's BPMC Position: Q4 2021 in Review

Cormorant Asset Management sold out of Blueprint Medicines (BPMC) in Q4 2021, closing a stake of 150,000 shares — an estimated $15.4M sold.

Cormorant Asset Management first reported a position in BPMC in Q2 2015 and held it in 25 quarters. The position peaked at $39.6M in Q1 2018. 280 funds tracked by Wall St. Rank hold BPMC as of Q4 2021.

  • Cormorant Asset Management reported no remaining Blueprint Medicines position as of Q4 2021 after selling out during the quarter.
  • Cormorant Asset Management sold 150,000 Blueprint Medicines shares in Q4 2021, an estimated $15.4M.
  • Cormorant Asset Management first reported a position in Blueprint Medicines in Q2 2015 and held it in 25 quarters.
  • Cormorant Asset Management's Blueprint Medicines position peaked at $39.6M in Q1 2018.
  • 280 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2021.

Based on Cormorant Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.